Cariprazine in the Management of Negative Symptoms of Schizophrenia: State of the art and Future Perspectives

References

• CalabreseF, TaraziFI, RacagniG, RivaMA. The role of dopamine D3 receptors in the mechanism of action of cariprazine. CNS Spectr.25, 1–9 (2019).
   Web of Science ®Google Scholar
• McCutcheonRA, KrystalJH, HowesOD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry19(1), 15–33 (2019).
   Web of Science ®Google Scholar
• McCutcheonRA, Abi-DarghamA, HowesOD. Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci.42(3), 205–220 (2019).
   PubMed Web of Science ®Google Scholar
• RabinowitzJ, BerardoCG, Bugarski-KirolaD, MarderS. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis. Schizophr. Res.150(2–3), 339–342 (2013).
   PubMed Web of Science ®Google Scholar
• CarbonM, CorrellCU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr.19(Suppl. 1), 38–52 (2019).
   Google Scholar
• StahlSM. Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes. CNS Spectr.22(5), 375–384 (2017).
   PubMed Web of Science ®Google Scholar
• SinghSP, CroudaceT, AminSet al.Three-year outcome of first-episode psychoses in an established community psychiatric service. Br. J. Psychiatry176, 210–216 (2000).
   PubMed Web of Science ®Google Scholar
• JääskeläinenE, JuolaP, HirvonenNet al.A systematic review and meta-analysis of recovery in schizophrenia. Schizophr. Bull.39(6), 1296–1306 (2013).
   PubMed Web of Science ®Google Scholar
• The Schizophrenia Commission. The abandoned illness. https://www.rethink.org/media/2637/the-abandoned-illness-final.pdf
   Google Scholar
• KaneJM, RobinsonDG, SchoolerNRet al.Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE early treatment program. Am. J. Psychiatry173(4), 362–372 (2016).
   PubMed Web of Science ®Google Scholar
• ChanSKW, ChanSWY, PangHHet al.Association of an early intervention service for psychosis with suicide rate among patients with first-episode schizophrenia-spectrum disorders. JAMA Psychiatry75(5), 458–464 (2018).
   PubMed Web of Science ®Google Scholar
• Álvarez-JiménezM, GleesonJF, HenryLPet al.Road to full recovery: longitudinal relationship between symptomatic remission and psychosocial recovery in first-episode psychosis over 7.5 years. Psychol. Med.42(3), 595–606 (2012).
   PubMed Web of Science ®Google Scholar
• CorrellCU, GallingB, PawarAet al.Comparison of early intervention services vs treatment as usual for early-phase psychosis: a systematic review, meta-analysis, and meta-regression. JAMA Psychiatry75(6), 555–565 (2018).
   PubMed Web of Science ®Google Scholar
• Santesteban-EcharriO, PainoM, RiceSet al.Predictors of functional recovery in first-episode psychosis: a systematic review and meta-analysis of longitudinal studies. Clin. Psychol. Rev.58, 59–75 (2017).
   PubMed Web of Science ®Google Scholar
• MillanMJ, FoneK, StecklerT, HoranWP. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur. Neuropsychopharmacol.24(5), 645–692 (2014).
   PubMed Web of Science ®Google Scholar
• PatelR, JayatillekeN, BroadbentMet al.Negative symptoms in schizophrenia: a study in a large clinical sample of patients using a novel automated method. BMJ Open5(9), e007619 (2015).
   PubMed Web of Science ®Google Scholar
• BowieCR, LeungWW, ReichenbergAet al.Predicting schizophrenia patients’ real-world behavior with specific neuropsychological and functional capacity measures. Biol. Psychiatry63(5), 505–511 (2008).
   PubMed Web of Science ®Google Scholar
• DownsJ, DeanH, LechlerSet al.Negative symptoms in early-onset psychosis and their association with antipsychotic treatment failure. Schizophr. Bull.45(1), 69–79 (2019).
   PubMed Web of Science ®Google Scholar
• KirkpatrickB, FentonWS, CarpenterWTJr, MarderSR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull.32(2), 214–219 (2006).
   PubMed Web of Science ®Google Scholar
• AlphsL, MorlockR, CoonC, van WilligenburgA, PanagidesJ. The 4-item negative symptom assessment (NSA-4) instrument: a simple tool for evaluating negative symptoms in schizophrenia following brief training. Psychiatry (Edgmont)7(7), 26–32 (2010).
   PubMedGoogle Scholar
• MarderSR, AlphsL, AnghelescuIGet al.Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophr. Res.150(2–3), 328–333 (2013).
   PubMed Web of Science ®Google Scholar
• CarbonM, CorrellCU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin. Neurosci.16(4), 505–524 (2014).
   PubMed Web of Science ®Google Scholar
• FervahaG, FoussiasG, AgidO, RemingtonG. Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia. Acta Psychiatr. Scand.130(4), 290–299 (2014).
   PubMed Web of Science ®Google Scholar
• RitsnerMS, ArbitmanM, LiskerA. Anhedonia is an important factor of health-related quality-of-life deficit in schizophrenia and schizoaffective disorder. J. Nerv. Ment. Dis.199(11), 845–853 (2011).
   PubMed Web of Science ®Google Scholar
• CorrellCU, SchoolerNR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr. Dis. Treat.16, 519–534 (2020).
   PubMed Web of Science ®Google Scholar
• GreenMF, NuechterleinKH. Should schizophrenia be treated as a neurocognitive disorder?Schizophr. Bull.25(2), 309–319 (1999).
   PubMed Web of Science ®Google Scholar
• Fusar-PoliP, PapanastasiouE, StahlDet al.Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr. Bull.41(4), 892–899 (2017).
   Web of Science ®Google Scholar
• SokoloffP, LeFoll B. The dopamine D3 receptor, a quarter century later. Eur. J. Neurosci.45(1), 2–19 (2017).
   PubMed Web of Science ®Google Scholar
• HerschSM, CiliaxBJ, GutekunstCAet al.Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J. Neurosci.15(7 Pt 2), 5222–5237 (1995).
   PubMed Web of Science ®Google Scholar
• GraceAA. Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression. Nat. Rev. Neurosci.17(8), 524–532 (2016).
   PubMed Web of Science ®Google Scholar
• HadleyJA, NenertR, KraguljacNVet al.Ventral tegmental area/midbrain functional connectivity and response to antipsychotic medication in schizophrenia. Neuropsychopharmacology39(4), 1020–1030 (2014).
   PubMed Web of Science ®Google Scholar
• StahlSM. Mechanism of action of cariprazine. CNS Spectr.21(2), 123–127 (2016).
   PubMed Web of Science ®Google Scholar
• MaedaK, SuginoH, AkazawaHet al.Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J. Pharmacol. Exp. Ther.350(3), 589–604 (2014).
   PubMed Web of Science ®Google Scholar
• KissB, HorváthA, NémethyZet al.Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J. Pharmacol. Exp. Ther.333(1), 328–340 (2010).
   PubMed Web of Science ®Google Scholar
• GirgisRR, SlifsteinM, D'SouzaDet al.Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. Psychopharmacology (Berl).233(19–20), 3503–3512 (2016).
   PubMed Web of Science ®Google Scholar
• NakamuraT, KubotaT, IwakajiA, ImadaM, KapásM, MorioY. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des. Devel. Ther.10, 327–338 (2016).
   PubMed Web of Science ®Google Scholar
• NémethG, LaszlovszkyI, CzoborPet al.Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet389(10074), 1103–1113 (2017).
   PubMed Web of Science ®Google Scholar
• NICE. NICE guideline psychosis and schizophrenia in adults: prevention and management. (2014). https://www.nice.org.uk/guidance/cg178/resources/psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-35109758952133
   Google Scholar
• MarderS, FleischhackerWW, EarleyWet al.Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: pooled analyses from 3 Phase II/III studies. Eur. Neuropsychopharmacol.29(1), 127–136 (2019).
   PubMed Web of Science ®Google Scholar
• DurgamS, StaraceA, LiDet al.An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a Phase II, randomized clinical trial. Schizophr. Res.152(2–3), 450–457 (2014).
   PubMed Web of Science ®Google Scholar
• DurgamS, CutlerAJ, LuKet al.Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, Phase III, randomized, double-blind, placebo- and active-controlled trial. J. Clin. Psychiatry76(12), e1574–1582 (2015).
   PubMed Web of Science ®Google Scholar
• KaneJM, ZukinS, WangYet al.Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, Phase III clinical trial. J. Clin. Psychopharmacol.35(4), 367–373 (2015).
   PubMed Web of Science ®Google Scholar
• FleischhackerW, GalderisiS, LaszlovszkyIet al.The efficacy of cariprazine in negative symptoms of schizophrenia: post hoc analyses of PANSS individual items and PANSS-derived factors. Eur. Psychiatry58, 1–9 (2019).
   PubMed Web of Science ®Google Scholar
• CitromeL, DurgamS, LuK, FergusonP, LaszlovszkyI. The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials. J. Clin. Psychiatry77(1), 109–115 (2016).
   PubMed Web of Science ®Google Scholar
• EarleyW, GuoH, DanielDet al.Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: a post hoc analysis of pooled data. Schizophr. Res.204, 282–288 (2019).
   PubMed Web of Science ®Google Scholar
• DurgamS, EarleyW, LiRet al.Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. Schizophr. Res.176(2–3), 264–271 (2016).
   PubMed Web of Science ®Google Scholar
• CorrellCU, PotkinSG, ZhongY, HarsányiJ, SzatmáriB, EarleyW. Long-term remission with cariprazine treatment in patients with schizophrenia: a post hoc analysis of a randomized, double-blind, placebo-controlled, relapse prevention trial. J. Clin. Psychiatry80(2), pii: 18m12495 (2019).
   Google Scholar
• CorrellCU, JainR, MeyerJMet al.Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation. Neuropsychiatr. Dis. Treat.15, 2537–2550 (2019).
   PubMed Web of Science ®Google Scholar
• NasrallahH, EarleyW, CutlerAJet al.The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis. BMC Psychiatry17(1), 305 (2017).
   PubMedGoogle Scholar
• CutlerAJ, DurgamS, WangYet al.Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS Spectr.23(1), 39–50 (2018).
   PubMed Web of Science ®Google Scholar
• HuhnM, NikolakopoulouA, Schneider-ThomaJet al.Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet394(10202), 939–951 (2019).
   PubMed Web of Science ®Google Scholar
• TandonR, TargumSD, NasrallahHA, RossR. Treatment effectiveness in schizophrenia consortium. Strategies for maximizing clinical effectiveness in the treatment of schizophrenia. J. Psychiatr. Pract.12(6), 348–363 (2006).
   PubMedGoogle Scholar
• NovickD, HaroJM, SuarezD, VietaE, NaberD. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr. Res.108(1–3), 223–230 (2009).
   PubMed Web of Science ®Google Scholar
• LeuchtS, CiprianiA, SpineliLet al.Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet382(9896), 951–962 (2013).
   PubMed Web of Science ®Google Scholar
• BarnesTR. Schizophrenia Consensus Group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol.25(5), 567–620 (2011).
   PubMed Web of Science ®Google Scholar
• CorrellCU. Balancing efficacy and safety in treatment with antipsychotics. CNS Spectr.12(17 Suppl. 10), 12–20 (2007).
   PubMed Web of Science ®Google Scholar
• DeHert M, DetrauxJ, van WinkelR, YuW, CorrellCU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat. Rev. Endocrinol.8(2), 114–126 (2011).
   PubMed Web of Science ®Google Scholar
• PillingerT, McCutcheonRA, VanoLet al.Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry7, 64–77 (2020).
   PubMed Web of Science ®Google Scholar